212268-39-8 Usage
Uses
Used in Inorganic Bromide Production:
3-Fluoro-5-methylbenzyl bromide is used as a precursor in the production of inorganic bromides. Its bromine atom can be utilized to generate various inorganic bromide compounds, which have applications in different fields such as flame retardants, water treatment, and chemical synthesis.
Used in Pharmaceutical Industry:
3-Fluoro-5-methylbenzyl bromide is used as a pharmaceutical intermediate. Its unique structure allows it to be a key component in the synthesis of various pharmaceutical compounds, contributing to the development of new drugs and therapeutic agents. Its presence in the molecular structure can influence the pharmacological properties, such as potency, selectivity, and bioavailability, of the final drug product.
Check Digit Verification of cas no
The CAS Registry Mumber 212268-39-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,2,2,6 and 8 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 212268-39:
(8*2)+(7*1)+(6*2)+(5*2)+(4*6)+(3*8)+(2*3)+(1*9)=108
108 % 10 = 8
So 212268-39-8 is a valid CAS Registry Number.
212268-39-8Relevant articles and documents
Development of a Phase-Transfer-Catalyzed, [2,3]-Wittig Rearrangement
Denmark, Scott E.,Cullen, Lindsey R.
, p. 11818 - 11848 (2015/12/11)
An investigation into the use of phase-transfer catalysis for the [2,3]-sigmatropic rearrangement of allyloxy carbonyl compounds is described. Initial studies focused on identifying viable substrate classes that would undergo selective [2,3]-rearrangement under phase-transfer catalysis. Under certain conditions, the [2,3]-sigmatropic rearrangement of allyloxy carbonyl compounds takes place in the presence of a phase-transfer agent, providing a rare example of a phase-transfer-catalyzed unimolecular reaction. In the course of this investigation, it was found that catalysis is dependent on several variables including base concentration, catalyst structure, and substrate lipophilicity. Preliminary testing of chiral, nonracemic phase-transfer catalysts has shown promising levels of enantioselectivity for future development.
